Current issues with β2-adrenoceptor agonists: Pharmacology and molecular and cellular mechanisms

Clinical Reviews in Allergy and Immunology

Volumn 31, Issue 2-3, 2006, Pages 119-130

  Anderson, Gary P ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

2 Adrenoreceptor; LABAs; Lung; Signal transduction; Tachyphylaxis

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY] PROPYL]AMINO]ETHOXY]SALICYLAMIDE; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; ADRENALIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FORMOTEROL; GLUCOCORTICOID; GUANINE NUCLEOTIDE BINDING PROTEIN; SALBUTAMOL; SALMETEROL; STEROID; TERBUTALINE; UNCLASSIFIED DRUG; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT;

ASTHMA; BRONCHODILATATION; CLINICAL TRIAL; DNA POLYMORPHISM; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; HEART ARRHYTHMIA; HUMAN; INFLAMMATION; LUNG FUNCTION; MAST CELL DEGRANULATION; NEUROTRANSMISSION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TACHYPHYLAXIS; TORSADE DES POINTES; TREATMENT RESPONSE; DRUG POTENTIATION; PHYSIOLOGY;

ADRENERGIC BETA-AGONISTS; BRONCHODILATOR AGENTS; HUMANS; RECEPTORS, ADRENERGIC, BETA-2; SIGNAL TRANSDUCTION;

EID: 33751329255     PISSN: 10800549     EISSN: None     Source Type: Journal    
DOI: 10.1385/CRIAI:31:2:119     Document Type: Review

References (79)

1. Carstairs, J. R., Nimmo, A. J., and Barnes, P. J. (1985), Autoradiographic visualization of beta-adrenoceptor subtypes in human lung. Am. Rev. Respir. Dis. 132, 541-547.
2. Mak, J. C., Nishikawa, M., Haddad, E. B., et al. (1996), Localisation and expression of beta-adrenoceptor subtype mRNAs in human lung. Eur. J. Pharmacol. 302, 215-221.
3. Anderson, G. P. (1993), Long acting inhaled beta-adrenoceptor agonists the comparative pharmacology of formoterol and salmeterol. Agents Actions Suppl. 43, 253-269.
4. Anderson, G. P. (1993), Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. Life Sci. 52, 2145-2160.
5. O'Donnell, S. R. and Anderson, G. P. (1995), The effects of formoterol on plasma exudation produced by a localized acute inflammatory response to bradykinin in the tracheal mucosa of rats in vivo. Br. J. Pharmacol. 116, 1571-1576.
6. Bowden, J. J., Anderson, G. P., Lefevre, P. M., Sulakvelidze, I., and McDonald, D. M. (1997), Characterization of tolerance to the anti-leakage effect of formoterol in rat airways. Eur. J. Pharmacol. 338, 83-87.
7. Anderson, G. P. (2000), Interactions between corticosteroids and beta-adrenergic agonists in asthma disease induction, progression, and exacerbation. Am. J. Respir. Crit. Care Med. 161, S188-S196.
8. Barnes, P. J. (1993), Beta-adrenoceptors on smooth muscle, nerves and inflammatory cells. Life Sci. 52, 2101-2109.
9. Johnson, M., Butchers, P. R., Coleman, R. A., et al. (1993), The pharmacology of salmeterol. Life Sci. 52, 2131-2143.
10. Kips, J. C., O'Connor, B. J., Inman, M. D., Svensson, K., Pauwels, R. A., and O'Byrne, P. M. (2000), A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am. J. Respir. Crit. Care Med. 161, 996-1001.
11. Maneechotesuwan, K., Essilfie-Quaye, S., Meah, S., et al. (2005), Formoterol attenuates neutrophilic airway inflammation in asthma. Chest 128, 1936-1942.
12. Roth, M., Johnson, P. R., Rudiger, J. J., et al. (2002), Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 360, 1293-1299.
13. Edwards, M. R., Johnson, M. W., and Johnston, S. L. (2006), Combination therapy: synergistic suppression of virus induced chemokines in airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 34, 616-624.
14. Kruse, M., Rosenkranz, B., Dobson, C., Ayre, G., and Horowitz, A. (2005), Safety and tolerability of high-dose formoterol (Aerolizer) and salbutamol (pMDI) in patients with mild/moderate, persistent asthma. Pulm. Pharmacol. Ther. 18, 229-234.
15. Goldkorn, A., Diotto, P., Burgess, C., et al. (2004), The pulmonary and extra-pulmonary effects of high-dose formoterol in COPD: a comparison with salbutamol. Respirology 9, 102-108.
16. Burgess, C., Ayson, M., Rajasingham, S., Crane, J., Della Cioppa, G., and Till, M. D. (1998), The extrapulmonary effects of increasing doses of formoterol in patients with asthma. Eur. J. Clin. Pharmacol. 54, 141-147.
17. Cazzola, M., Imperatore, F., Salzillo, A., et al. (1998), Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 114, 411-415.
18. Nelson, H. S. (2006), Is there a problem with inhaled long-acting beta-adrenergic agonists? J. Allergy Clin. Immunol. 117, 3-16.
19. Martinez, F. D. (2005), Safety of long-acting beta-agonists-an urgent need to clear the air. N. Engl. J. Med. 353, 2637-2639.
20. Taylor, D. R., Drazen, J. M., Herbison, G. P., Yandava, C. N., Hancox, R. J., and Town, G. I. (2000), Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax 55, 762-767.
21. Israel, E., Drazen, J. M., Liggett, S. B., et al. (2000), The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am. J. Respir. Crit. Care Med. 162, 75-80.
22. Ramsdale, E. H., Otis, J., Kline, P. A., Gontovnick, L. S., Hargreave, F. E., and O'Byrne, P. M. (1991), Prolonged protection against methacholine-induced bronchoconstriction by the inhaled beta 2-agonist formoterol. Am. Rev. Respir Dis. 143, 998-1001.
23. Pauwels, R. A., Lofdahl, C. G., Postma, D. S., et al. (1997), Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N. Engl. J. Med. 337, 1405-1411.
24. O'Connor, R. D., Rosenzweig, J. R., Stanford, R. H., et al. (2005), Asthma-related exacerbations, therapy switching, and therapy discontinuation: a comparison of 3 commonly used controller regimens. Ann. Allergy Asthma Immunol. 95, 535-540.
25. Cullum, V. A., Farmer, J. B., Jack, D., and Levy, G. P. (1969), Salbutamol: a new, selective beta-adrenoceptive receptor stimulant. Br. J. Pharmacol. 35, 141-151.
26. Jack, D. (1991), The 1990 Lilly Prize Lecture. A way of looking at agonism and antagonism: lessons from salbutamol, salmeterol and other beta-adrenoceptor agonists. Br. J. Clin. Pharmacol. 31, 501-514.
27. Tomioka, K., Yamada, T., and Ida, H. (1981), Anti-allergic activities of the beta-adrenoceptor stimulant formoterol (BD 40A). Arch. Int. Pharmacodyn. Ther. 250, 279-292.
28. Mita, H. and Shida, T. (1983), Anti-allergic activity of formoterol, a new beta-adrenoceptor stimulant, and salbutamol in human leukocytes and human lung tissue. Allergy 38, 547-552.
29. Tomioka, K., Yamada, T., and Tachikawa, S. (1984), Effects of formoterol (BD 40A), a beta-adrenoceptor stimulant, on isolated guinea-pig lung parenchymal strips and antigen-induced SRS-A release in rats. Arch. Int. Pharmacodyn. Ther. 267, 91-102.
30. Green, S. A., Spasoff, A. P., Coleman, R. A., Johnson, M., and Liggett, S. B. (1996), Sustained activation of a G protein-coupled receptor via "anchored" agonist binding. Molecular localization of the salmeterol exosite within the 2-adrenergic receptor. J. Biol. Chem. 271, 24,029-24,035.
31. Anderson, G. P., Linden, A., and Rabe, K. F. (1994), Why are long-acting beta-adrenoceptor agonists long-acting? Eur. Respir. J. 7, 569-578.
32. Guhan, A. R., Cooper, S., Oborne, J., Lewis, S., Bennett, J., and Tattersfield, A. E. (2000), Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 55, 650-656.
33. Bennett, J. and Tattersfield, A. E. (1997), Several studies have shown salmeterol to be more potent than salbutamol for systemic effects. B.M.J. 315, 121.
34. Barnes, P. J. and Pride, N. B. (1983), Dose-response curves to inhaled beta-adrenoceptor agonists in normal and asthmatic subjects. Br. J. Clin. Pharmacol. 15, 677-682.
35. Molimard, M., Naline, E., Zhang, Y., Le Gros, V., Begaud, B., and Advenier, C. (1998), Long- and short-acting beta2 adrenoceptor agonists: interactions in human contracted bronchi. Eur. Respir. J. 11, 583-588.
36. Nightingale, J. A., Rogers, D. F., and Barnes, P. J. (1999), Differential effect of formoterol on adenosine monophosphate and histamine reactivity in asthma. Am. J. Respir. Crit. Care Med. 159, 1786-1790.
37. Freddolino, P. L., Kalani, M. Y., Vaidehi, N., et al. (2004), Predicted 3D structure for the human beta 2 adrenergic receptor and its binding site for agonists and antagonists. Proc. Natl. Acad. Sci. USA 101, 2736-2741.
38. Dixon, R. A., Sigal, I. S., Rands, E., et al. (1987), Ligand binding to the beta-adrenergic receptor involves its rhodopsin-like core. Nature 326, 73-77.
39. Rands, E., Candelore, M. R., Cheung, A. H., Hill, W. S., Strader, C. D., and Dixon, R. A. (1990), Mutational analysis of beta-adrenergic receptor glycosylation. J. Biol. Chem. 265, 10,759-10,764.
40. O'Dowd, B. F., Hnatowich, M., Caron, M. G., Lefkowitz, R. J., and Bouvier, M. (1989), Palmitoylation of the human beta 2-adrenergic receptor. Mutation of Cys341 in the carboxyl tail leads to an uncoupled nonpalmitoylated form of the receptor. J. Biol. Chem. 264, 7564-7569.
41. Moffett, S., Adam, L., Bonin, H., Loisel, T. P., Bouvier, M., and Mouillac, B. (1996), Palmitoylated cysteine 341 modulates phosphorylation of the beta2-adrenergic receptor by the cAMP-dependent protein kinase. J. Biol. Chem. 271, 21,490-21,497.
42. Moffett, S., Rousseau, G., Lagace, M., and Bouvier, M. (2001), The palmitoylation state of the beta(2)-adrenergic receptor regulates the synergistic action of cyclic AMP-dependent protein kinase and beta-adrenergic receptor kinase involved in its phosphorylation and desensitization. J. Neurochem. 76, 269-279.
43. Strader, C. D., Sigal, I. S., Register, R. B., Candelore, M. R., Rands, E., and Dixon, R. A. (1987), Identification of residues required for ligand binding to the beta-adrenergic receptor. Proc. Natl. Acad. Sci. USA 84, 4384-4388.
44. Dixon, R. A., Sigal, I. S., Candelore, M. R., et al. (1987), Structural features required for ligand binding to the beta-adrenergic receptor. Embo. J. 6, 3269-3275.
45. Truong-Tran, A. Q., Grosser, D., Ruffin, R. E., Murgia, C., and Zalewski, P. D. (2003), Apoptosis in the normal and inflamed airway epithelium: role of zinc in epithelial protection and procaspase-3 regulation. Biochem. Pharmacol. 66, 1459-1468.
46. Swaminath, G., Lee, T. W., and Kobilka, B. (2003), Identification of an allosteric binding site for Zn2+ on the beta2 adrenergic receptor. J. Biol. Chem. 278, 352-356.
47. Green, S. A., Rathz, D. A., Schuster, A. J., and Liggett, S. B. (2001), The Ile164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s). Eur. J. Pharmacol. 421, 141-147.
48. Salahpour, A., Angers, S., Mercier, J. F., Lagace, M., Marullo, S., and Bouvier, M. (2004), Homodimerization of the beta2-adrenergic receptor as a prerequisite for cell surface targeting. J. Biol. Chem. 279, 33,390-33,397.
49. Hebert, T. E., Loisel, T. P., Adam, L., Ethier, N., Onge, S. S., and Bouvier, M. (1998), Functional rescue of a constitutively desensitized beta2AR through receptor dimerization. Biochem. J. 330 (Pt 1), 287-293.
50. Zhu, W. Z., Chakir, K., Zhang, S., et al. (2005), Heterodimerization of beta1- and beta2-adrenergic receptor subtypes optimizes beta-adrenergic modulation of cardiac contractility. Circ. Res. 97, 244-251.
51. Breit, A., Lagace, M., and Bouvier, M. (2004), Heterooligomerization between beta2- and beta3-adrenergic receptors generates a beta-adrenergic signaling unit with distinct functional properties. J. Biol. Chem. 279, 28,756-28,765.
52. Mercier, J. F., Salahpour, A., Angers, S., Breit, A., and Bouvier, M. (2002), Quantitative assessment of beta 1- and beta 2-adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer. J. Biol. Chem. 277, 44,925-44,931.
53. Lavoie, C., Mercier, J. F., Salahpour, A., et al. (2002), Beta 1/beta 2-adrenergic receptor heterodimerization regulates beta 2-adrenergic receptor internalization and ERK signaling efficacy. J. Biol. Chem. 277, 35,402-35,410.
54. Salahpour, A., Bonin, H., Bhalla, S., Petaja-Repo, U., and Bouvier, M. (2003), Biochemical characterization of beta2-adrenergic receptor dimers and oligomers. Biol. Chem. 384, 117-123.
55. Spicuzza, L., Belvisi, M. G., Birrell, M. A., Barnes, P. J., Hele, D. J., and Giembycz, M. A. (2001), Evidence that the anti-spasmogenic effect of the betaadrenoceptor agonist, isoprenaline, on guinea-pig trachealis is not mediated by cyclic AMP-dependent protein kinase. Br. J. Pharmacol. 133, 1201-1212.
56. Hall, R. A., Ostedgaard, L. S., Premont, R. T., et al. (1998), A C-terminal motif found in the beta2-adrenergic receptor, P2Y1 receptor and cystic fibrosis transmembrane conductance regulator determines binding to the Na+/H+ exchanger regulatory factor family of PDZ proteins. Proc. Natl. Acad. Sci. USA 95, 8496-8501.
57. Hall, R. A., Premont, R. T., Chow, C. W., et al. (1998), The beta2-adrenergic receptor interacts with the Na+/H+-exchanger regulatory factor to control Na+/H+ exchange. Nature 392, 626-630.
58. Cook, S. J., Small, R. C., Berry, J. L., Chiu, P., Downing, S. J., and Foster, R. W. (1993), Beta-adrenoceptor subtypes and the opening of plasmalemmal K(+)-channels in trachealis muscle: electrophysiological and mechanical studies in guinea-pig tissue. Br. J. Pharmacol. 109, 1140-1148.
59. Shenoy, S. K., McDonald, P. H., Kohout, T. A., and Lefkowitz, R. J. (2001), Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science 294, 1307-1313.
60. Lavine, N., Ethier, N., Oak, J. N., et al. (2002), G protein-coupled receptors form stable complexes with inwardly rectifying potassium channels and adenylyl cyclase. J. Biol. Chem. 277, 46,010-46,019.
61. Iyer, V., Tran, T. M., Foster, E., Dai, W., Clark, R. B., and Knoll, B. J. (2006), Differential phosphorylation and dephosphorylation of beta(2)-adrenoceptor sites Ser262 and Ser355,356. Br. J. Pharmacol. 147, 249-259.
62. FitzGerald, J. M., Chapman, K. R., Della Cioppa, G., et al. (1999), Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group. J. Allergy Clin. Immunol. 103, 427-435.
63. Aziz, I., Tan, K. S., Hall, I. P., Devlin, M. M., and Lipworth, B. J. (1998), Subsensitivity to bronchoprotection against adenosine monophosphate challenge following regular once-daily formoterol. Eur. Respir. J. 12, 580-584.
64. Lee, D. K., Currie, G. P., Hall, I. P., Lima, J. J., and Lipworth, B. J. (2004), The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. Br. J. Clin. Pharmacol. 57, 68-75.
65. Tan, K. S., Grove, A., McLean, A., Gnosspelius, Y., Hall, I. P., and Lipworth, B. J. (1997), Systemic corticosteriod rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. Am. J. Respir. Crit. Care Med. 156, 28-35.
66. Lipworth, B. J. and Aziz, I. (2000), Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration. Chest 117, 156-162.
67. Boulet, L. P., Cartier, A., Milot, J., Cote, J., Malo, J. L., and Laviolette, M. (1998), Tolerance to the protective effects of salmeterol on methacholine-induced bronchoconstriction: influence of inhaled corticosteroids. Eur. Respir. J. 11, 1091-1097.
68. Nishikawa, M., Mak, J. C., and Barnes, P. J. (1996), Effect of short- and long-acting beta 2-adrenoceptor agonists on pulmonary beta 2-adrenoceptor expression in human lung. Eur. J. Pharmacol. 318, 123-129.
69. Lemoine, H., Overlack, C., Kohl, A., Worth, H., and Reinhardt, D. (1992), Formoterol, fenoterol, and salbutamol as partial agonists for relaxation of maximally contracted guinea pig tracheae: comparison of relaxation with receptor binding. Lung 170, 163-180.
70. Lemoine, H. and Overlack, C. (1992), Highly potent beta-2 sympathomimetics convert to less potent partial agonists as relaxants of guinea pig tracheae maximally contracted by carbachol. Comparison of relaxation with receptor binding and adenylate cyclase stimulation. J. Pharmacol. Exp. Ther. 261, 258-270.
71. Campbell, P. T., Hnatowich, M., O'Dowd, B. F., Caron, M. G., Lefkowitz, R. J., and Hausdorff, W. P. (1991), Mutations of the human beta 2-adrenergic receptor that impair coupling to Gs interfere with receptor down-regulation but not sequestration. Mol. Pharmacol. 39, 192-198.
72. Jockers, R., Angers, S., Da Silva, A., et al. (1999), Beta(2)-adrenergic receptor down-regulation. Evidence for a pathway that does not require endocytosis. J. Biol. Chem. 274, 28,900-28,908.
73. Finney, P. A., Belvisi, M. G., Donnelly, L. E., et al. (2000), Albuterol-induced downregulation of Gsalpha accounts for pulmonary beta(2)-adrenoceptor desensitization in vivo. J. Clin. Invest. 106, 125-135.
74. Van Amsterdam, R. G., Meurs, H., Ten Berge, R. E., Veninga, N. C., Brouwer, F., and Zaagsma, J. (1990), Role of phosphoinositide metabolism in human bronchial smooth muscle contraction and in functional antagonism by beta-adrenoceptor agonists. Am. Rev. Respir. Dis. 142, 1124-1128.
75. Wills-Karp, M., Uchida, Y., Lee, J. Y., Jinot, J., Hirata, A., and Hirata, F. (1993), Organ culture with proinflammatory cytokines reproduces impairment of the beta-adrenoceptor-mediated relaxation in tracheas of a guinea pig antigen model. Am. J. Respir. Cell Mol. Biol. 8, 153-159.
76. Bai, T. R., Mak, J. C., and Barnes, P. J. (1992), A comparison of beta-adrenergic receptors and in vitro relaxant responses to isoproterenol in asthmatic airway smooth muscle. Am. J. Respir. Cell Mol. Biol. 6, 647-651.
77. Bai, T. R. (1991), Abnormalities in airway smooth muscle in fatal asthma. A comparison between trachea and bronchus. Am. Rev. Respir. Dis. 143, 441-443.
78. McGraw, D. W., Almoosa, K. F., Paul, R. J., Kobilka, B. K., and Liggett, S. B. (2003), Antithetic regulation by beta-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway beta-agonist paradox. J. Clin. Invest. 112, 619-626.
79. Callaerts-Vegh, Z., Evans, K. L., Dudekula, N., et al. (2004), Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. Proc. Natl. Acad. Sci. USA 101, 4948-4953.